NASDAQ: SGPSpyglass Pharma Inc Stock
$21.18+2.37 (+12.6%)
Updated Jun 26, 2026
SGP Price
$21.18
Fair Value Price
$2.84
Market Cap
$708.12M
52 Week Low
$17.06
52 Week High
$32.44
P/E
N/A
P/B
2.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
1.47
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SGP Overview
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SGP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SGP news, forecast changes, insider trades & much more!
SGP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SGP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGP ($21.18) is overvalued by 647% relative to our estimate of its Fair Value price of $2.84 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SGP ($21.18) is not significantly undervalued (647%) relative to our estimate of its Fair Value price of $2.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SGP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more SGP due diligence checks available for Premium users.
Valuation
SGP fair value
Fair Value of SGP stock based on Discounted Cash Flow (DCF)
Price
$21.18
Fair Value
$2.84
Overvalued by
647.00%
SGP ($21.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SGP ($21.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SGP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.83x
Industry
5.34x
SGP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGP's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.8M
Profit Margin
0%
Assets to liabilities
Assets
$258.4M
Liabilities
$8.3M
Debt to equity
0.03
SGP's short-term assets ($253.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGP's short-term assets ($253.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.5M
Investing
-$1.7M
Financing
$157.8M
SGP vs Biotech Stocks
Spyglass Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.